Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role

Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.

When Merck & Co. Inc.'s former Chief Medical Officer Michael Rosenblatt retired earlier this year, he had no shortage of opportunities to go back to work, which is what he'll do in September as the CMO at Flagship Ventures – a newly created position in which Rosenblatt will mentor the venture capital firm's portfolio companies.

"Flagship proposed something creative and compelling," Rosenblatt said in an interview, noting that this may be the first time a VC firm has hired a CMO. But now that Flagship's investment portfolio includes about 40 therapeutics companies with more than 40 clinical trials under way, it makes sense to have an in-house mentor to guide biopharma entrepreneurs through the research and development process

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By 

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By 

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.